Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety and efficacy of GS-6624 (formerly AB0024) in idiopathic pulmonary fibrosis has completed. The trial sponsor is Gilead Sciences…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• GS-6624 (formerly AB0024) (GS-6624)

Snippet

Sponsor: Gilead Sciences | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED